Skip to main content
OpenTrials
Completed

NCT Number: NCT00189488

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Graft Versus Host Disease Graft vs Host Disease Hematologic Diseases Hematologic Malignancies Hematologic Neoplasms Hemic and Lymphatic Diseases Immune System Diseases Mouth Diseases Neoplasms Neoplasms by Site Stomatitis Stomatognathic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with hematologic malignancies (including myelodysplastic syndromes [MDS]) who are considered eligible for Cyclophosphamide (Cy)/Total Body Irradiation(TBI) +/- Etoposide (VP-16); Total Body Irradiation(TBI)/ Etoposide(VP-16); Melphalan(Mel) / Total Body Irradiation(TBI); Busulfan(Bu)/ Cyclophosphamide(Cy); Busulfan(Bu)/ Melphalan (Mel); or Fludarabine(Flu)/ Melphalan(Mel) conditioning therapy with allogeneic stem cell support
  • Subjects with a 6/6 Human Leukocyte Antigen (HLA)-matched family member or unrelated donor who would provide donor marrow/ peripheral progenitor stem cells. [For unrelated matched donors, molecular typing of class I and class II is mandatory]
  • Karnofsky Performance Status >= 70%
  • 18 years of age or older at time of informed consent
  • Before any study-specific procedure, the appropriate written informed consent must be obtained

Exclusion criteria

  • Cancer other than Non-Hodgkin's lymphoma, Hodgkin's disease, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome or multiple myeloma (except: adequately treated basal cell carcinoma of the skin)
  • Prior autologous or allogeneic bone marrow or peripheral blood stem cell transplantation
  • Previous use of palifermin
  • Current active infection (including human immunodeficiency virus (HIV) and hepatitis) or oral mucositis
  • Congestive heart failure as defined by New York Heart Association class III or IV
  • Graft T-cell depletion for Graft-versus-host disease (GVHD) prophylaxis
  • Inadequate renal function (serum creatinine > 1.5x the upper limit of normal per the institutional guidelines or clearance < 40 ml/min adjusted for age)
  • Inadequate liver function (total bilirubin > 1.5x the upper limit of normal, aspartate aminotransferase (AST) > 3x upper limit of normal and/or alanine aminotransferase (ALT) > 3x upper limit of normal per the institutional guidelines)
  • Inadequate pulmonary function as measured by a corrected DLCO (diffusing capacity of the lung for carbon monoxide lung function test) <50% of predicted
  • Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)
  • Subject of child-bearing potential is evidently pregnant (e.g. positive human chorionic gonadotropin- HCG test) or is breast feeding during Part A of the study
  • Subject or partner of subject is not using or refuses to use adequate contraceptive precautions during Part A of the study
  • Subject has known sensitivity to any of the products to be administered during dosing including Escherichia coli-derived products
  • Subject was previously randomized into this study
  • Subject will not be available for follow-up assessments
  • Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures

Treatment and study plan

Palifermin

Drug

Administered as an intravenous (IV) bolus.

Other names: Recombinant human keratinocyte growth factor (rHuKGF), Kepivance

Placebo

Drug

Administered as an intravenous (IV) bolus.

Conditioning Regimen

Other

Each participant received 1 of the following conditioning regimens:

  • Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)
  • TBI/VP-16
  • Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)
  • Busulfan (Bu)/Cy
  • Bu/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])
  • Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])

Allogeneic stem cell transplant

Procedure

Allogeneic marrow/peripheral blood progenitor cell transplantation

methotrexate

Drug

Primary outcomes

  1. Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD)

    Time frame: From transplant (Day 0) until Day 100

    GVHD was graded using the modified Keystone Criteria weekly during the first 2 months after stem cell infusion, then every other week until Day 100.

    Severity was determined clinically (based on physical exam and laboratory serum values) and from biopsies of affected organs whenever possible. The degree of GVHD in individual organs was scored by at least 2 assessors.

    Grade 3 GVHD = total bilirubin 3.1 - 15.0 mg/dL or ≥ 1000 mL/day diarrhea or severe abdominal pain with/without ileus.

    Grade 4 GVHD = skin involvement with bullous formation or total bilirubin > 15.0 mg/dL.

Secondary outcomes

  1. Number of Participants With Grade 2 to 4 Acute Graft Versus Host Disease (GVHD)

    Time frame: From transplant (Day 0) until Day 100

    GVHD was graded using the modified Keystone Criteria weekly during the first 2 months after stem cell infusion, then every other week until Day 100.

    Severity was determined clinically (based on physical exam and laboratory serum values) and from biopsies of affected organs whenever possible. The degree of GVHD in individual organs was scored by at least 2 assessors.

    Grade 2 GVHD = > 50% skin involvement or total bilirubin 2.0 - 3.0 mg/dL or 500 - 999 mL/day diarrhea, or persistent nausea with histologic evidence.

    Grade 3 GVHD = total bilirubin 3.1 - 15.0 mg/dL or ≥ 1000 mL/day diarrhea or severe abdominal pain with/without ileus.

    Grade 4 GVHD = skin involvement with bullous formation or total bilirubin > 15.0 mg/dL.

  2. Number of Participants With Day 11 Methotrexate Graft Versus Host Disease Prophylaxis Administration

    Time frame: Day 11

    Low dose methotrexate is widely used in regimens to prophylax against acute GVHD. Methotrexate was administered on days 1, 3, 6 and 11 (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2, respectively.

  3. Number of Participants With Severe (Grade 3 or 4) Oral Mucositis

    Time frame: From transplant (Day 0) until Day 100

    Oral cavity assessments were performed by a trained assessor using the World Health Organization (WHO) oral toxicity scale. Daily oral mucositis assessments were performed:

    • while participants were hospitalized, including the day of discharge (maximum until day 28);
    • after discharge until the oral mucositis grade returns to a WHO grade ≤ 2.

    The WHO oral toxicity criteria are: Grade 0 = None; Grade 1 = Soreness, erythema; Grade 2 = Erythema, ulcers, ability to eat solids; Grade 3 = Ulcers, requires liquid diet; Grade 4 = Alimentation not possible.

  4. Duration of Severe Oral Mucositis (WHO Grade 3 and 4)

    Time frame: From transplant (Day 0) until Day 100

    The duration of severe oral mucositis was calculated as the number of days from the onset of severe mucositis (first time a WHO grade of 3 or 4 was observed) to the last day when severe mucositis was observed. If oral mucositis assessments were recorded as missed visits immediately prior to or immediately after severe mucositis was recorded, the missed visits were considered to be severe oral mucositis.

  5. Number of Participants With Parenteral or Transdermal Opioid Analgesic Use

    Time frame: From transplant (Day 0) until Day 100

    Includes nonprophylactic intravenous opioid analgesics (fentanyl, morphine, morphine sulphate, hydromorphone, meperidine) and transdermal opioid analgesics (fentanyl patch) for the indication of oral mucositis and dysphagia.

  6. Duration of Hospitalization

    Time frame: From transplant (Day 0) until Day 100

    Duration of hospitalization was defined as the number of days a participant stayed in hospital (hospitalized) during the period starting from the day of the transplant (Day 0) to the 100th day following the transplant.

  7. Area Under the Curve (AUC) of Mouth and Throat Soreness Score

    Time frame: The first day of study drug administration through Day 28.

    The modified Oral Mucositis Daily Questionnaire (OMDQ) is a self-reported tool that evaluates overall health, mouth and throat soreness (MTS) and activity limitations due to MTS.

    The modified OMDQ was completed once daily beginning with the first day of study drug administration through day 28.

    The area under the curve of mouth and throat soreness score was assessed from the question "How much mouth and throat soreness did you experience in the past 24 hours?" Participants answered on a scale from 0 (no soreness) to 4 (extreme soreness).

Sponsors and collaborators

Lead sponsor

Swedish Orphan Biovitrum

Industry

Collaborators

  • Amgen

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation

Important dates

Study start
2005
Primary completion
2008
Study completion
2013
First posted
Sep 19, 2005
Registry last updated
Sep 15, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.